Fibrinogen-to-prealbumin and C-reactive protein-to-prealbumin ratios as prognostic indicators in severe fever with thrombocytopenia syndrome.

Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE

Original Publication: Lausanne : Frontiers Media SA

C-Reactive Protein*/analysis ; C-Reactive Protein*/metabolism ; Fibrinogen*/analysis ; Fibrinogen*/metabolism ; Severe Fever with Thrombocytopenia Syndrome*/blood ; Severe Fever with Thrombocytopenia Syndrome*/mortality ; ROC Curve* ; Prealbumin*/analysis ; Prealbumin*/metabolism; Humans ; Male ; Female ; Prognosis ; Middle Aged ; Aged ; Biomarkers/blood ; Risk Factors ; Adult ; Phlebovirus ; Kaplan-Meier Estimate ; Retrospective Studies

Background: The primary aim of this study is to investigate the correlation between serum levels of fibrinogen-to-prealbumin ratio (FPR) and C-reactive protein-to-prealbumin ratio (CPR) and prognostic outcomes among patients with severe fever with thrombocytopenia syndrome (SFTS). SFTS, characterized by elevated mortality rates, represents a substantial public health challenge as an emerging infectious disease.
Methods: The study included 159 patients with SFTS. Clinical and laboratory data were compared between the survival and death groups. Univariate and multivariate logistic regression analysis were utilized to identify independent risk factors for mortality. The predictive efficacy of FPR and CPR was evaluated using receiver operating characteristic (ROC) curve. Survival analysis was conducted using the Kaplan-Meier curve and the log-rank test was employed for comparison.
Results: The death group exhibited significantly elevated levels of FPR and CPR compared to the survival group ( P < 0.05). Multivariate logistic regression analysis confirmed that both FPR and CPR independently correlated with a poorer prognosis among patients with SFTS. The ROC curve analysis indicated that FPR and CPR had superior predictive capabilities compared to C-reactive protein and fibrinogen. Kaplan-Meier survival analysis demonstrated that patients with SFTS who have FPR > 0.045 (log-rank test; χ2 = 17.370, P < 0.001) or CPR > 0.05 (log-rank test; χ2 = 19.442, P < 0.001) experienced significantly lower survival rates within a 30-day follow-up period.
Conclusion: Elevated levels of FPR and CPR serve as distinct risk factors for mortality among patients with SFTS, indicating their potential to predict an unfavorable prognosis in these patients.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Zhang, Liu, Qiao and He.)

Signal Transduct Target Ther. 2021 Apr 16;6(1):145. (PMID: 33859168)
BMC Nephrol. 2011 Jun 29;12:30. (PMID: 21714897)
World J Surg Oncol. 2020 Jan 13;18(1):9. (PMID: 31931816)
Sci Rep. 2023 Jan 27;13(1):1538. (PMID: 36707667)
Yonago Acta Med. 2019 Dec 13;63(1):8-19. (PMID: 32158328)
Anaesth Intensive Care. 2011 Sep;39(5):854-61. (PMID: 21970129)
BMC Infect Dis. 2022 Mar 6;22(1):225. (PMID: 35249544)
Zoonoses Public Health. 2018 Dec;65(8):903-907. (PMID: 29862661)
Front Med (Lausanne). 2022 Apr 29;9:879982. (PMID: 35572999)
Clin Infect Dis. 2012 Feb 15;54(4):527-33. (PMID: 22144540)
Medicine (Baltimore). 2020 Jan;99(2):e18727. (PMID: 31914089)
Emerg Infect Dis. 2018 Sep;24(9):. (PMID: 30124424)
EBioMedicine. 2021 Oct;72:103591. (PMID: 34563924)
Endocr Connect. 2020 Aug;9(8):858-863. (PMID: 32880377)
Ann Clin Lab Sci. 2021 Jan;51(1):82-89. (PMID: 33653784)
Clin Infect Dis. 2013 Nov;57(9):1292-9. (PMID: 23965284)
J Infect Dis. 2014 Mar;209(6):816-27. (PMID: 24231186)
J Inflamm Res. 2021 Oct 29;14:5647-5652. (PMID: 34744448)
J Cardiol. 2021 Oct;78(4):308-313. (PMID: 34120831)
Emerg Infect Dis. 2013 Nov;19(11):1892-4. (PMID: 24206586)
COPD. 2020 Feb;17(1):22-28. (PMID: 31820666)
Langenbecks Arch Surg. 2022 Aug;407(5):1901-1909. (PMID: 35420308)
N Engl J Med. 2011 Apr 21;364(16):1523-32. (PMID: 21410387)
PLoS One. 2022 Nov 8;17(11):e0276159. (PMID: 36346823)
Korean J Clin Oncol. 2023 Jun;19(1):11-17. (PMID: 37449394)
Int J Infect Dis. 2022 Dec;125:10-16. (PMID: 36241165)
Biomark Med. 2017 Apr;11(4):329-337. (PMID: 28326826)
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):579-590. (PMID: 36933563)
Emerg Infect Dis. 2019 May;25(5):1029-1031. (PMID: 31002059)
Front Cell Infect Microbiol. 2022 Feb 08;12:725642. (PMID: 35211422)
Heart. 2014 Nov;100(22):1780-5. (PMID: 24986895)
Open Forum Infect Dis. 2023 Oct 13;10(11):ofad509. (PMID: 37937042)
N Engl J Med. 2012 Aug 30;367(9):834-41. (PMID: 22931317)
Pak J Med Sci. 2022 May-Jun;38(5):1250-1254. (PMID: 35799744)
Arch Virol. 2016 Oct;161(10):2921-49. (PMID: 27424026)
World Neurosurg. 2022 Apr;160:e442-e453. (PMID: 35051638)
Ann Palliat Med. 2021 Nov;10(11):11653-11663. (PMID: 34872290)
J Med Virol. 2022 Nov;94(11):5375-5384. (PMID: 35790466)
Int J Clin Pract. 2015 Oct;69(10):1121-8. (PMID: 26133088)
J Med Virol. 2022 Dec;94(12):5933-5942. (PMID: 36030552)
Clin Infect Dis. 2021 Dec 6;73(11):e3851-e3858. (PMID: 33068430)

Keywords: C-reactive protein-to-prealbumin ratio; fibrinogen-to-prealbumin ratio; prognosis; risk factor; severe fever with thrombocytopenia syndrome

9007-41-4 (C-Reactive Protein)
9001-32-5 (Fibrinogen)
0 (Prealbumin)
0 (Biomarkers)

Date Created: 20240625 Date Completed: 20240625 Latest Revision: 20240715

20240715

PMC11194340

10.3389/fcimb.2024.1397789

38915920